CN105219863A - 错配修复基因hMLH1异常剪接体的定性及定量检测试剂盒及其用途 - Google Patents
错配修复基因hMLH1异常剪接体的定性及定量检测试剂盒及其用途 Download PDFInfo
- Publication number
- CN105219863A CN105219863A CN201510690928.1A CN201510690928A CN105219863A CN 105219863 A CN105219863 A CN 105219863A CN 201510690928 A CN201510690928 A CN 201510690928A CN 105219863 A CN105219863 A CN 105219863A
- Authority
- CN
- China
- Prior art keywords
- pcr
- qualitative
- hmlh1
- hmlh1 gene
- test kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 46
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 14
- 230000001594 aberrant effect Effects 0.000 title claims abstract description 13
- 238000001514 detection method Methods 0.000 title claims abstract description 11
- 230000033607 mismatch repair Effects 0.000 title claims abstract description 4
- 239000002299 complementary DNA Substances 0.000 claims abstract description 15
- 238000012360 testing method Methods 0.000 claims abstract description 14
- 238000011529 RT qPCR Methods 0.000 claims abstract description 11
- 230000003321 amplification Effects 0.000 claims abstract description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 7
- 210000001324 spliceosome Anatomy 0.000 claims abstract description 7
- 238000012408 PCR amplification Methods 0.000 claims abstract description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims abstract description 6
- 238000012163 sequencing technique Methods 0.000 claims abstract description 6
- 239000012807 PCR reagent Substances 0.000 claims abstract 2
- 229920002684 Sepharose Polymers 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 10
- 108020004999 messenger RNA Proteins 0.000 abstract description 8
- 238000000246 agarose gel electrophoresis Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 2
- 238000004445 quantitative analysis Methods 0.000 abstract description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000012300 Sequence Analysis Methods 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 14
- 206010017758 gastric cancer Diseases 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 201000011549 stomach cancer Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 201000000498 stomach carcinoma Diseases 0.000 description 5
- 230000004087 circulation Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 101150086731 ges-1 gene Proteins 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 238000010819 mRNA expression detection Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
Abstract
本发明涉及错配修复基因hMLH1异常剪接体的定性及定量检测试剂盒及其用途。试剂盒的主要成分包括:(1)hMLH1基因cDNA?PCR定性扩增与测序引物2对;(2)hMLH1基因cDNA实时定量PCR扩增引物8对;(3)RT-PCR试剂;(4)PCR扩增用试剂。通过本试剂盒得到的PCR扩增产物,可通过琼脂糖凝胶电泳结合DNA序列分析确认mRNA表达产物,并采用实时定量PCR方法定量分析mRNA表达水平。本试剂盒具有高效的mRNA检出作用。用于hMLH1基因异常剪接体的检测。
Description
技术领域
本发明涉及一种hMLH1基因异常剪接体检测试剂盒,特别涉及其在东亚胃癌高发人群的mRNA表达分析与后果评估。
背景技术
胃癌(Gastriccancer,GC)是严重危害人类健康的常见恶性肿瘤之一,其发病是一个多因素、多步骤、多基因参与的复杂病理过程。人类错配修复基因hMLH1胚系突变是遗传性非息肉性结直肠癌的重要病因,而在胃癌高发的东亚人群,部分家族性胃癌的发病亦与hMLH1基因功能异常相关。pre-mRNA选择性剪接是真核生物基因转录后表达调控的关键环节之一,构成蛋白质多样性的一个主要来源,也是生物细胞功能平衡系统调控的重要组成部分。选择性剪接产物的自然平衡维持细胞的正常功能,剪接过程的异常可导致这种功能平衡的破坏,使得细胞某些关键基因的功能性蛋白表达模式改变,与肿瘤等多种人类疾病的发病风险增高相关联。但是目前尚缺乏系统检测hMLH1基因剪接体异常的方法。因此有必要开发一种方便快捷的hMLH1基因异常剪接体检测方法,以用于胃癌的病因学分析。
发明内容
本发明的目的是提供一种hMLH1基因异常剪接体的定性及定量检测试剂盒及其应用。
本检测试剂盒主要包括以下成分:
(1)hMLH1基因cDNAPCR定性扩增与测序引物2对,各对引物序列见表1;
(2)hMLH1基因cDNASYBRGreen法实时定量PCR扩增引物及探针8对,各对引物序列见表2;
(3)RNA提取试剂、逆转录酶,PCR扩增试剂,如dNTP、ExTaqHotStart聚合酶及SYBRGreen试剂等。
表1hMLH1基因RT-PCR引物序列
表2hMLH1基因SYBRGreen法实时定量PCR引物序列
本试剂盒扩增出的RT-PCR产物可以采用以下方式进行mRNA表达定性检测:将PCR产物进行琼脂糖凝胶电泳,根据电泳条带位置进行分析,并对于电泳条带纯化后测序分析。
本试剂盒RNA逆转录产物还可以在ABIStepOnePlusReal-TimePCRSystem仪器上开展实时定量PCR反应,进行mRNA表达定量检测。
试剂盒中,还可以有琼脂糖凝胶、RNA提取试剂、DNA纯化试剂及SYBRGreen试剂等。
本发明所说的试剂盒用于检测hMLH1基因异常剪接体。
本试剂盒的检测hMLH1基因异常剪接体的步骤包括:
(1)提取组织或细胞RNA。
(2)RNA逆转录。
(3)hMLH1基因cDNAPCR扩增。
分别扩增hMLH1基因外显子10-11及外显子16–18区域。引物如表1所示。反应体系为20μl:TaKaRaExTaqHS聚合酶0.15μl、10×EXTaqbuffer2.5μl、dNTPMixture(2.5mMeach)2.5μl、上游引物(10μM)1μl、下游引物(10μM)1μl、cDNA1μl、ddH2O11.85μl。反应条件:95℃预变性5min;95℃变性30sec,58℃复性30sec,72℃延伸30sec,40个循环;再72℃延伸10min。
将PCR产物进行1.5%琼脂糖凝胶电泳,EB分辨条带,通过条带差异区分野生型或外显子跳跃型。条带经切胶纯化测序鉴定。
(4)hMLH1基因cDNAqPCR扩增。
SYBRGreen法实时定量PCR分析hMLH1基因外显子10-11区域和外显子16-17区域不同转录产物。引物如表2所示。反应体系为10μl:SYBR5μl、ROXReferenceDye0.2μl、上游引物(10μM)0.2μl、下游引物(10μM)0.2μl、cDNA1μl、ddH2O3.4μl。反应条件:95℃30sec;95℃15sec,60℃30sec,共40个循环。
本试剂盒具有高效的异常剪接体检测作用。实施实例中报道,对于胃癌患者,针对hMLH1基因外显子10-11区域,采用试剂盒的功能评估方法提出,除了正常剪接的mRNA产物,还存在hMLH1外显子10跳跃、11跳跃及10-11跳跃等异常剪接产物,对于胃癌形成可能具有病因学意义。本试剂盒在胃癌患者hMLH1异常剪接体检测及病因学意义分析上具有重要作用。
附图说明
图1A是胃癌患者瘤组织RNA的RT-PCR图。图示hMLH1基因外显子10-11区域的扩增条带。M为分子量标记。
图1B是图1A中截短条带的测序图及示意图:图示hMLH1基因外显子10、11及10-11跳跃的序列。
图2是胃癌患者瘤组织及同源正常组织RNA的SYBRGreen法RT-qPCR图。图示hMLH1基因正常转录产物及delEx10、delEx10-11转录产物表达水平。
图3是胃粘膜上皮细胞系GES-1、胃癌细胞系SGC-7901、BGC-823及MGC80-3中,RNA的SYBRGreen法RT-qPCR图。图示hMLH1基因正常转录产物及delEx10、delEx11及delEx10-11转录产物表达水平。
具体实施方式
实施例1:中国胃癌患者hMLH1外显子10-11区域mRNA异常剪接体的定性及定量分析
针对hMLH1外显子10-11区域,RT-PCR分析mRNA异常剪接体:提取患者瘤组织RNA,逆转录为cDNA,选择‘hMLH1基因cDNAPCR定性扩增与测序引物’第1对引物(F:5'-TGGAAATGCTGTTAGTCGAGAA-3',R:5'-AGACGAGGTCAGACTTGTTGTG-3'),扩增hMLH1基因外显子10-11区域。反应体系为20μl:TaKaRaExTaqHS聚合酶0.15μl、10×EXTaqbuffer2.5μl、dNTPMixture(2.5mMeach)2.5μl、上游引物(10μM)1μl、下游引物(10μM)1μl、cDNA1μl、ddH2O11.85μl。反应条件:95℃预变性5min;95℃变性30sec,58℃复性30sec,72℃延伸30sec,40个循环;再72℃延伸10min。将PCR产物进行1.5%琼脂糖凝胶电泳,EB分辨条带,通过条带差异区分野生型或外显子跳跃型。条带经切胶纯化测序鉴定。图1为hMLH1基因外显子10-11的PCR扩增图,由图1可见,hMLH1基因外显子10-11区域除了存在hMLH1基因正常转录产物(448bp),还扩增出不同长度的截短转录产物。条带经切胶纯化,采用BigDyeTerminatorV3.1试剂盒,在ABI3130基因分析仪(美国ABI公司)上测序,确认截短条带354bp、294bp和200bp分别是hMLH1基因外显子10缺失(delEx10)、外显子11缺失(delEx11)和外显子10-11缺失(delEx10-11)。将分别形成编码265、315和292个氨基酸的截短蛋白(图1)。
在30例胃癌患者瘤组织及同源正常组织cDNA中,开展转录特异的定量PCR分析:提取患者瘤组织RNA,逆转录为cDNA,选择表2中‘hMLH1基因cDNA实时定量PCR扩增引物’第1-4对引物(即SEQIDNo.5-12),SYBRGreen法实时定量PCR分析hMLH1基因外显子10-11区域不同转录产物。反应体系为10μl:SYBR5μl、ROXReferenceDye0.2μl、上游引物(10μM)0.2μl、下游引物(10μM)0.2μl、cDNA1μl、ddH2O3.4μl。反应条件:95℃30sec;95℃15sec,60℃30sec,共40个循环。结果显示除了正常RNA表达产物,多数均存在hMLH1delEx10及delEx10-11异常转录产物(图2)。采用上述同样的转录特异的定量PCR分析,经体外实验揭示,胃粘膜上皮细胞系GES-1、胃癌细胞系SGC-7901、BGC-823及MGC80-3中均存在hMLH1delEx10、delEx11及delEx10-11异常转录产物。总体上胃癌细胞系中hMLH1基因外显子10-11区域的异常转录产物显著高于人胃粘膜细胞系,但不同胃癌细胞系在hMLH1基因外显子10-11区域的异常转录产物的比例不尽相同(图3)。
Claims (3)
1.一种错配修复基因hMLH1异常剪接体的定性及定量检测试剂盒,其特征在于包括以下成分:
(1)hMLH1基因cDNAPCR定性扩增与测序引物2对;(2)hMLH1基因cDNA实时定量PCR扩增引物及探针8对;(3)RT-PCR试剂;(4)PCR扩增用试剂;
所说的2对hMLH1基因cDNAPCR定性扩增与测序引物序列如下:
第1对:
F:5'-TGGAAATGCTGTTAGTCGAGAA-3'
R:5'-AGACGAGGTCAGACTTGTTGTG-3'
第2对:
F:5'-CACCAAGCTTAGTGAAGAACTG-3'
R:5'-GAAAGAAGAACACATCCCAC-3'
所说的8对hMLH1基因cDNA实时定量PCR扩增引物序列如下:
第1对:
F:5'-CTTCTTACTCTTCATCAACCATCGT-3'
R:5'-CTGATTTCTAAACTGAGGTACAGG-3'
第2对:
F:5'-TTCATCAACCTTTAGAAATCAGTCC-3'
R:5'-TAGCAAAGTCTGGGTGAAGTACATC-3'
第3对:
F:5'-CATTCCTGTACCTCAGACTTTG-3'
R:5'-CATAGACCTTATCACTACTTCC-3'
第4对:
F:5'-TCTTCATCAACCACTTTGCTAC-3'
R:5’-CATAGACCTTATCACTACTTCC-3’
第5对:
F:5'-GAAATTGATGAGGAAGGGAACCTG-3'
R:5'-CAGGCACTTCACTCTGCTGGCCTG-3'
第6对:
F:5'-CAGGTTATCGGAAGGGAACCTG-3'
R:5'-CAGGCACTTCACTCTGCTGGCCTG-3'
第7对:
F:5'-GAAATTGATGAGGTGAATTGGGAC-3'
R:5’-CAGGCACTTCACTCTGCTGGCCTG-3’
第8对:
F:5'-CAGGTTATCGAGTGAAGTGCCTG-3'
R:5'-GAAAGAAGAACACATCCCAC-3'。
2.根据权利要求1所述的试剂盒,其特征在于,还包括琼脂糖凝胶,SYBRGreen试剂。
3.权利要求1所说的试剂盒用于检测hMLH1基因异常剪接体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510690928.1A CN105219863A (zh) | 2015-10-22 | 2015-10-22 | 错配修复基因hMLH1异常剪接体的定性及定量检测试剂盒及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510690928.1A CN105219863A (zh) | 2015-10-22 | 2015-10-22 | 错配修复基因hMLH1异常剪接体的定性及定量检测试剂盒及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105219863A true CN105219863A (zh) | 2016-01-06 |
Family
ID=54989129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510690928.1A Pending CN105219863A (zh) | 2015-10-22 | 2015-10-22 | 错配修复基因hMLH1异常剪接体的定性及定量检测试剂盒及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105219863A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1145097A (zh) * | 1994-01-27 | 1997-03-12 | 人体基因组科学有限公司 | 人dna错配修复蛋白 |
WO2011119553A1 (en) * | 2010-03-26 | 2011-09-29 | The Ohio State University | Materials and methods related to modulation of mismatch repair and genomic stability by mir-155 |
CN102634521A (zh) * | 2012-03-07 | 2012-08-15 | 哈尔滨医科大学 | 中国北方大肠癌患者hMSH2基因的新突变及其用途 |
CN102643823A (zh) * | 2012-03-07 | 2012-08-22 | 哈尔滨医科大学 | 中国北方大肠癌患者hMLH1基因的新突变及其用途 |
CN102787173A (zh) * | 2012-09-06 | 2012-11-21 | 南京大学 | 上皮型钙黏蛋白表达基因CDH1 pre-mRNA选择性剪接检测试剂盒及其用途 |
-
2015
- 2015-10-22 CN CN201510690928.1A patent/CN105219863A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1145097A (zh) * | 1994-01-27 | 1997-03-12 | 人体基因组科学有限公司 | 人dna错配修复蛋白 |
WO2011119553A1 (en) * | 2010-03-26 | 2011-09-29 | The Ohio State University | Materials and methods related to modulation of mismatch repair and genomic stability by mir-155 |
CN102634521A (zh) * | 2012-03-07 | 2012-08-15 | 哈尔滨医科大学 | 中国北方大肠癌患者hMSH2基因的新突变及其用途 |
CN102643823A (zh) * | 2012-03-07 | 2012-08-22 | 哈尔滨医科大学 | 中国北方大肠癌患者hMLH1基因的新突变及其用途 |
CN102787173A (zh) * | 2012-09-06 | 2012-11-21 | 南京大学 | 上皮型钙黏蛋白表达基因CDH1 pre-mRNA选择性剪接检测试剂盒及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107058544B (zh) | 14个功能性杀伤细胞免疫球蛋白样受体KIRs基因同步测序分型的方法 | |
Sterne-Weiler et al. | Loss of exon identity is a common mechanism of human inherited disease | |
WO2017076299A1 (zh) | 一种多重pcr引物及应用 | |
Roffey et al. | A rare mutation in the amelogenin gene and its potential investigative ramifications | |
JP6968894B2 (ja) | メチル化dnaの多重検出方法 | |
EP2029773A1 (en) | Methods and kits for linking polymorphic sequences to expanded repeat mutations | |
CN105331611A (zh) | 一种基于下一代测序技术检测egfr/kras/braf基因突变位点的多重pcr引物和方法及应用 | |
CN102439174B (zh) | 基于检测slc45a3-elk4融合转录子的用于诊断前列腺癌的组合物和方法 | |
CN106048008A (zh) | 一种egfr基因超低频突变检测试剂盒 | |
CN106011230A (zh) | 用于检测碎片化dna目标区域的引物组合物及其应用 | |
CN103602745B (zh) | 一种用于检测鸡pmel17基因显性白羽位点基因型的引物、试剂盒及检测方法 | |
CN105219863A (zh) | 错配修复基因hMLH1异常剪接体的定性及定量检测试剂盒及其用途 | |
CN102787173B (zh) | 上皮型钙黏蛋白表达基因CDH1 pre-mRNA选择性剪接检测试剂盒及其用途 | |
Sand et al. | Novel splice variants of CXCR4 identified by transcriptome sequencing | |
Kostrzewska-Poczekaj et al. | Recurrent amplification in the 22q11 region in laryngeal squamous cell carcinoma results in overexpression of the CRKL but not the MAPK1 oncogene | |
CN102732514A (zh) | 趋化因子受体9基因作为牛优良超数排卵性状分子标记的鉴定方法及其应用 | |
ES2698002T3 (es) | Genes que proporcionan resistencia al mildiú pulverulento en Cucumis Sativus | |
ATE313631T1 (de) | Dna polymerase lambda und ihre verwendungen | |
CN102102129B (zh) | 利用MutS蛋白在基因组范围内检测单核苷酸多态性或小的插入和缺失的方法 | |
CN105483117B (zh) | 一种提高聚合酶链式反应特异性的方法 | |
CN108875314B (zh) | 一种基于表观遗传学修饰差异的靶基因的检测方法 | |
CN103789436B (zh) | 一种基于人工修饰引物的定量突变检测系统 | |
Murray et al. | The genome-wide sequence specificity of DNA cleavage by bleomycin analogues in human cells | |
CN103275986B (zh) | 京海黄鸡产蛋数分子标记及应用 | |
CN105695575A (zh) | 55个snp位点多色荧光复合检测的方法及试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160106 |
|
WD01 | Invention patent application deemed withdrawn after publication |